Amie: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Amie Health, Inc.’s website, https://tryamie.com, FDA Establishment Identifier (FEI) 3044000672, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “amie” on the pictured label, suggesting Amie is the compounder of those drugs when in fact it is not.”

2. 2

   ““Ozempic, Mounjaro, and Wegovy contain the same active ingredients as our compounded versions (semaglutide and tirzepatide).””

3. 3

   ““All our treatments use FDA-approved active ingredients….””

4. 4

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

tryamie.com returned a live storefront when we checked in August 2026, but selling an on-demand libido formula for women with clinician review and a refund-if-not-approved promise. We saw no GLP-1, semaglutide or tirzepatide product on the homepage at that check. We did not review every page or complete an intake, so this is not confirmation that the products named in the letter were withdrawn.

Two things here are worth separating. The first is the sentence FDA quoted, which is built the wrong way round: instead of saying the compounded vial matches the brand, it says the brands match the compounded vial. The grammar quietly promotes the compounded product to the standard against which Ozempic, Mounjaro and Wegovy are measured — and the approval still belongs to the brands. The second is what we found when we looked. The GLP-1 catalogue FDA reviewed in March 2026 was not on the homepage in August 2026; the company was selling something else entirely. That is a normal thing for a young telehealth brand to do and it is not a shutdown, but it does affect how you use a price you saw quoted somewhere. Catalogues in this market move fast, and a listed GLP-1 price is worth re-checking on the seller's own site before you treat it as current.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Amie failed to respond.